ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer

ClinicalTrials.gov ID: NCT03733210

Public ClinicalTrials.gov record NCT03733210. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 9:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Pilot Study Evaluating Panitumumab-IRDye800 and 89Zr-Panitumumab for Dual-Modality Imaging for Nodal Staging in Head and Neck Cancer

Study identification

NCT ID
NCT03733210
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Andrei Iagaru
Other
Enrollment
14 participants

Conditions and interventions

Interventions

  • 89-Zirconium (Zr-89) Panitumumab Drug
  • Da Vinci Firefly Imaging System Device
  • Explorer Air camera Device
  • FIS-00 fluorescence imaging system (FIS) Device
  • IGP-ELVIS-v4 Macroscopic Specimen Imager Device
  • Leica fluorescence microscope Device
  • Odyssey CLx Imaging System Device
  • PDE-NEO II camera Device
  • Panitumumab-IRDye800 Drug
  • Pearl Triology Imaging System Device
  • Pinpoint IR IR9000 fluorescence imaging system (FIS) Device
  • SPY-PHI IR9000 fluorescence imaging system (FIS) Device
  • Vevo 3100 LAZR-X Device

Drug · Device

Eligibility (public fields only)

Age range
19 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 6, 2019
Primary completion
Dec 10, 2020
Completion
Aug 8, 2021
Last update posted
May 18, 2023

2019 – 2021

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Stanford Cancer Institute Palo Alto Palo Alto California 94304

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03733210, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 18, 2023 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03733210 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →